Loading…
Eupraxia Pharmaceuticals Inc. is projected to rise to $8.16 by 2027, a +27% move from its current price of $6.40. EPRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $6.18 | $6.41 | $6.64 | +0.10% |
| Aug 4 | $6.10 | $6.41 | $6.74 | +0.19% |
| Aug 5 | $6.04 | $6.42 | $6.82 | +0.29% |
| Aug 6 | $5.99 | $6.42 | $6.89 | +0.38% |
| Aug 7 | $5.94 | $6.43 | $6.96 | +0.48% |
| Aug 8 | $5.90 | $6.44 | $7.02 | +0.57% |
| Aug 9 | $5.87 | $6.44 | $7.07 | +0.67% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.87 | $6.44 | $7.07 | +0.67% |
| Week 2 | $5.68 | $6.49 | $7.40 | +1.34% |
| Week 3 | $5.56 | $6.53 | $7.67 | +2.02% |
| Week 4 | $5.45 | $6.57 | $7.92 | +2.70% |
| Week 5 | $5.37 | $6.62 | $8.15 | +3.39% |
| Week 6 | $5.30 | $6.66 | $8.37 | +4.08% |
| Week 7 | $5.24 | $6.71 | $8.58 | +4.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract conditions, such as eosinophilic esophagitis.
The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Eupraxia Pharmaceuticals Inc. (EPRX) is a stock in the healthcare biotechnology space. The current price is $6.16, reflecting a particular point in time for a clinical-stage company focusing on innovative drug-delivery solutions.
Its market cap stands at $402.41M, and the stock ranks 3158 by market metrics. The year-by-year forecast shows an upside trajectory, with the average price rising from $6.16 in 2026 to $39.45 in 2050 and maximums reaching $72.11 in 2050.
A major floor 17.7% below — a decisive break under it would weaken the trend.
The nearest floor, 9.2% below — buyers have tended to step in here.
The nearest ceiling, 8.1% above — a clean break opens room to run.
A major ceiling 23.3% above — clearing it would confirm fresh momentum.
Key EPRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EPRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.24 | Buy | $6.30 | Buy |
| MA 10 | $6.23 | Buy | $6.29 | Buy |
| MA 20 | $6.40 | Sell | $6.35 | Buy |
| MA 50 | $6.47 | Sell | $6.53 | Sell |
| MA 100 | $6.85 | Sell | $6.74 | Sell |
| MA 200 | $7.00 | Sell | $6.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.24 | Neutral |
| Stoch RSI (14) | 82.73 | Sell |
| CCI (20) | -0.93 | Neutral |
| Williams %R (14) | -24.36 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.84 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 75.64 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 49.26 | Neutral |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 6.30 | Buy |
| ADX (14) | 9.43 | Neutral |
| ATR (14) | 0.22 | Info |
The 30-day technical picture is currently bearish.
The RSI14 is 40, and the stock trades below the SMA50 of $6.68 and SMA200 of $6.99, signaling near-term softness relative to recent moving averages.
Key levels to watch are a support at $5.92 and a resistance at $6.92. The 30-day trading range spans from $5.17 to $7.34, and the annualized volatility sits at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.81 | $6.40 | $8.82 | 0% | Neutral | |
| $6.33 | $8.16 | $11.20 | +27% | Bullish | |
| $6.25 | $8.36 | $12.04 | +31% | Bullish | |
| $6.63 | $9.15 | $13.65 | +43% | Bullish | |
| $6.80 | $9.64 | $14.83 | +51% | Bullish | |
| $7.18 | $10.45 | $16.49 | +63% | Bullish | |
| $8.96 | $13.35 | $21.57 | +109% | Bullish | |
| $10.17 | $15.51 | $25.58 | +142% | Bullish | |
| $10.88 | $16.94 | $28.49 | +165% | Bullish | |
| $10.32 | $16.42 | $28.09 | +156% | Bullish | |
| $15.93 | $27.88 | $51.36 | +336% | Bullish | |
| $23.10 | $47.97 | $98.24 | +650% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.81 | $6.40 | $7.76 | +0.00% |
| September 2026 | $5.50 | $6.56 | $8.10 | +2.58% |
| October 2026 | $5.80 | $6.98 | $8.73 | +6.33% |
| November 2026 | $5.83 | $7.07 | $8.94 | +1.35% |
| December 2026 | $5.66 | $6.91 | $8.82 | -2.27% |
Click any year to see its month-by-month EPRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EPRX to range from $5.81 to $8.82 through 2026. The $6.40 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EPRX price prediction for 2027 points to an average of $8.16 (low $6.33, high $11.20) — a potential gain of +27% on today's $6.40. Buyers look set to stay in control over this stretch.
In 2028, EPRX is projected to trade between $6.25 and $12.04, averaging $8.36 — a potential gain of +31% from today's $6.40. That is up +3% on the projected 2027 average. Momentum favours further upside here.
Eupraxia Pharmaceuticals Inc.'s 2029 outlook centres on $9.15, within a $6.63 to $13.65 range. That is up +9% on the projected 2028 average. That marks a +43% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, EPRX could reach as high as $14.83, with a base case around $9.64 and support toward $6.80 — roughly +51% from $6.40. Momentum favours further upside here.
Expect EPRX to range from $7.18 to $16.49 through 2031. The $10.45 average target implies a +63% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The EPRX price prediction for 2032 points to an average of $13.35 (low $8.96, high $21.57) — a potential gain of +109% on today's $6.40. Momentum favours further upside here.
In 2033, EPRX is projected to trade between $10.17 and $25.58, averaging $15.51 — a potential gain of +142% from today's $6.40. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Eupraxia Pharmaceuticals Inc.'s 2034 outlook centres on $16.94, within a $10.88 to $28.49 range. That is up +9% on the projected 2033 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2035, EPRX could reach as high as $28.09, with a base case around $16.42 and support toward $10.32 — roughly +156% from $6.40. Buyers look set to stay in control over this stretch.
Expect EPRX to range from $15.93 to $51.36 through 2040. The $27.88 average target implies a +336% move from current prices. That is up +70% on the projected 2035 average. Momentum favours further upside here.
The EPRX price prediction for 2050 points to an average of $47.97 (low $23.10, high $98.24) — a potential gain of +650% on today's $6.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in EPRX today (≈ 156.25 EPRX) could be worth
$7,495.36
+$6,495.36 (+650%) by 2050 · US Dollar
Based on the average projected EPRX price of $47.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EPRXwould be worth at today's price.
$1,000 invested in EPRX on Jul 31, 2025 (≈ 185.185182 EPRX) would be worth
$1,185.19
+$185.19 (+18.5%) today · 1.19× · US Dollar
Based on a EPRX entry price of $5.4 vs. today's $6.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.81 | $1,101.55 | +10.2% |
| 1 month ago | $6.71 | $953.8 | -4.6% |
| 3 months ago | $7.89 | $811.15 | -18.9% |
| 6 months ago | $7.88 | $812.18 | -18.8% |
| 1 year ago | $5.4 | $1,185.19 | +18.5% |
| All time (2.3y) ago | $2.95 | $2,169.49 | +116.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EPRX forecast.
Our base-case forecast reaches $13.00 around 2032.
Implied market cap at $13.00: $849.25M
The multi-year forecast shows a bullish trajectory across the coming years. The 2027 average is $7.73 with a 25.4% ROI and bullish sentiment, followed by 2028 at $7.82 (26.9% ROI) and 2029 at $8.59 (39.5% ROI). By 2030, the average is projected at $9.14 with a 48.4% ROI, and by 2031 at $9.46 (53.5% ROI).
Further out, 2032 is $11.83 (92% ROI), 2033 is $13.63 (121.3% ROI), 2034 is $14.26 (131.6% ROI), and 2035 is $14.43 (134.2% ROI). The forecast accelerates toward 2040 with an average of $22.75 and a 269.3% ROI, and by 2050 the average is $39.45 with a 540.5% ROI. These figures reflect bullish sentiment but remain estimates, not guarantees, and should be interpreted with appropriate caution.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $9.14 with a minimum of $6.81 and a maximum of $13.21, and a 48.4% ROI; sentiment is BULLISH.
The forecast depicts bullish sentiment from 2027 onward, with averages rising from $7.73 in 2027 to $39.45 in 2050 and ROIs up to 540.5% by 2050. These are estimates, not guarantees.
Yes—the 2050 maximum forecast is $72.11, with a 540.5% ROI and bullish sentiment.
Current price is $6.16 and market cap is $402.41M.
Sentiment is BEARISH; RSI14 is 40. The SMA50 is $6.68 and the SMA200 is $6.99. Support is $5.92 and resistance is $6.92. The 30-day range is $5.17 to $7.34, with annualized volatility at 50%.
Eupraxia Pharmaceuticals Inc. Community Discussion
0Share your Eupraxia Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.